AGuIX®: an innovative nanodrug with the aim to improve radiotherapy treatment of cancer
« NH TherAguix has developed an innovative nano drug to improve cancer treatment by radiotherapy. Its pharmacological properties and its mode of action by bio-distribution allow it to act in the heart of tumors and confer it a pan-cancer potential.
This is a tremendous hope for many patients whose medical needs are currently unmet. »
Vincent Carrère, CEO of NH TherAguix
Some figures about NH TherAguix
YEARS OF CLINICAL RESEARCH
SCIENTIFIC PAPERS
PATENT FAMILIES
ON-GOING CLINICAL TRIALS
%
OF CANCER PATIENTS ARE TREATED BY RADIOTHERAPY
%
MORE PATIENTS TO BE TREATED WITH RADIOTHERAPY BY 2025
EVENTS
NH TherAguix appoints Vincent Carrère as Chief Executive Officer
NH TherAguix announced the appointment of Vincent Carrère as Chief Executive Officer (CEO).
PRESS RELEASE
NH TherAguix and Jean PERRIN Cancer Centre in Clermont-Ferrand announcement
NH TherAguix and Jean PERRIN Cancer Centre in Clermont-Ferrand announce the completion of phase I recruitment and the entry into Phase II for the Nano-GBM phase I/II trial in glioblastoma with the two first patients included. [button...
SCIENTIFIC PUBLICATIONS
T1 Mapping From MPRAGE Acquisitions: Application to the Measurement of the Concentration of Nanoparticles in Tumors for Theranostic Use
J Magn Reson Imaging. 2022 Oct 31. doi: 10.1002/jmri.28509A. Lavielle, F. Boux, J. Deborne, et al.